Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Director | August 14, 2026 | August 21, 2026 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 23, 2022 | June 27, 2022 |
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Chief Medical Officer | March 02, 2026 | March 04, 2026 |
| Natera, Inc.NTRA · Entity 2635 | Director | June 26, 2026 | July 01, 2026 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date August 14, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2036-08-14 | Direct | 44,964 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 44,964 · Balance 44,964 F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.
Atara Biotherapeutics, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,500 |
Reported balance
After 2022-06-23 transaction · row 1
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 20,500 · Balance 43,500 F1: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2032-06-22 | Direct | 31,500 |
Reported balance
After 2022-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-23 · Grant · Acquired 31,500 · Balance 31,500 F2: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 134,088 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 134,088 · Balance 134,088 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Natera, Inc.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,158 |
Ending reported balance
After 2026-06-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-26 · Grant · Acquired 1,571 · Balance 20,083 F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-06-26 · Grant · Acquired 75 · Balance 20,158 F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Travere Therapeutics, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,500 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 4,500 · Balance 46,000 Row 2 · 2026-06-12 · Sale · Disposed 4,500 · Balance 41,500 F1: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.38 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 4,500 · Balance 0 F2: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2025 Filed Jun 13, 2025 20:05 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 30,508 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086141 · ownership.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,508 Underlying: Common Stock · 30,508 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option shall vest in full on June 11, 2026, subject to the Reporting Person's continuous service through the vesting date, inclusive. Read SEC document |
| May 19, 2025 Filed May 19, 2025 21:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001549595-25-000077 · wk-form4_1747690345.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001415889-25-013496 · form4-05162025_070503.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-05-15 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013496 · form4-05162025_070503.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 25, 2025 Filed Apr 30, 2025 00:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-011550 · form4-04292025_080401.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,015 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 20:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001549595-25-000045 · wk-form4_1741896536.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-10 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning April 11, 2025, until the option is fully vested on March 11, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:04 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001415889-25-003529 · form4-02102025_110214.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:04 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $22.00 | $220,000.00 |
DisclosureSEC source: 0001415889-25-003529 · form4-02102025_110214.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,000 F1 · kind: This sale was made pursuant to a written plan adopted on August 16, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:04 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $17.44 | $174,400.00 |
DisclosureSEC source: 0001415889-25-003529 · form4-02102025_110214.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 5, 2025 02:15 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 92 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-003068 · form4-02042025_090201.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,899 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 01:36 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001415889-25-002003 · form4-01242025_010152.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 01:36 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 16,000 | $20.00 | $320,000.00 |
DisclosureSEC source: 0001415889-25-002003 · form4-01242025_010152.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,000 F1 · kind: This sale was made pursuant to a written plan adopted on August 16, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on July 19, 2016, with an expiration date of July 19, 2026. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 01:36 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 16,000 | $17.50 | $280,000.00 |
DisclosureSEC source: 0001415889-25-002003 · form4-01242025_010152.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 15,230 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · derivative · entry 10 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,230 shares Expires 2028-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $22.83 | $0.00 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · derivative · entry 9 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,983 | $149.98 | $297,407.96 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 8 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,807 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.87 to $150.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,106 | $148.74 | $313,249.60 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 7 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,790 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.35 to $149.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 9,467 | $147.31 | $1,394,619.74 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 6 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,896 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.067 to $147.96 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,770 | $146.26 | $258,871.35 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 5 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,363 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.87 to $146.45 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 16,404 | $145.21 | $2,381,996.95 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 4 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,133 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.85 to $145.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 5,500 | $144.26 | $793,419.00 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,537 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.81 to $144.70 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 15,230 | $24.42 | $371,916.60 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:50 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 22,000 | $22.83 | $502,260.00 |
DisclosureSEC source: 0001415889-24-027020 · form4-11152024_091103.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2024 Filed Oct 30, 2024 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-025713 · form4-10292024_091001.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,807 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 26, 2024 Filed Jul 31, 2024 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-020382 · form4-07302024_090702.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,683 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 2,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019063 · form4-07022024_090701.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,540 F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2025. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001415889-24-012844 · form4-05102024_040510.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2034-05-07 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012844 · form4-05102024_040510.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 26, 2024 Filed May 1, 2024 00:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-011829 · form4-04302024_080413.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,576 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 215 | $63.79 | $13,714.85 |
DisclosureSEC source: 0001415889-24-001998 · form4-01302024_080101.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,407 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $13,750 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 322 | $42.60 | $13,717.20 |
DisclosureSEC source: 0001415889-23-014635 · form4-10312023_091001.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,192 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $13,750 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 28, 2023 Filed Aug 2, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 264 | $48.48 | $12,798.72 |
DisclosureSEC source: 0001415889-23-011685 · form4-08012023_090801.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,870 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $12,802.20 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 4,255 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001415889-23-010848 · form4-07052023_090701.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,255 Underlying: Common Stock · 4,255 shares Expires 2033-06-08 F3 · derivative.exercise_date: The option shares shall vest and become exercisable in full on June 9, 2024. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010848 · form4-07052023_090701.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,606 F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 9, 2024. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionRestricted Stock Unit · Derivative | 3,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008882 · form4-05262023_090501.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU vested in full on May 25, 2023. F2 · derivative.expiration_date: The RSU vested in full on May 25, 2023. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 3,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-008882 · form4-05262023_090501.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:06 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 13,500 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-23-030967 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2033-05-16 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:06 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030967 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,500 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 14, 2023 Filed Apr 19, 2023 00:10 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 228 | $54.73 | $12,478.44 |
DisclosureSEC source: 0001415889-23-006656 · form4-04182023_080401.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,322 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $12,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 312 | $40.01 | $12,483.12 |
DisclosureSEC source: 0001415889-23-001143 · form4-01182023_090101.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,094 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $12,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| October 14, 2022 Filed Oct 19, 2022 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 275 | $45.42 | $12,490.50 |
DisclosureSEC source: 0001415889-22-010696 · form4-10182022_091001.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,782 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $12,500 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 08, 2022 Filed Jul 13, 2022 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Unit · Derivative | 344 | $36.31 | $12,490.64 |
DisclosureSEC source: 0001415889-22-007643 · form4-07122022_090701.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344 Underlying: Common Stock · 344 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: The RSUs were issued to the Reporting Person in lieu of retainer fees of $12,500 for service on the Issuer's Board of Directors. F3 · derivative.exercise_date: The RSUs are fully vested and may be exercised at any time. F3 · derivative.expiration_date: The RSUs are fully vested and may be exercised at any time. Read SEC document |
| July 08, 2022 Filed Sep 3, 2022 00:05 UTC Amendment | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 344 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009317 · form4a-09022022_080901.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $12,500 for service on the Issuer's Board of Directors. The previously filed Form 4 inadvertently reported the transaction on Table II. The RSUs were fully-vested at the time of issuance and should have been reported on Table I as reflected in this amendment. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001140361-22-024161 · form4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-024161 · form4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 27, 2022 Filed Jun 2, 2022 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 7,068 | $0.00 Strike: $41.19 | $0.00 |
DisclosureSEC source: 0001415889-22-006008 · form4-06012022_090621.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,068 Underlying: Common Stock · 7,068 shares Expires 2032-05-25 F3 · derivative.exercise_date: The option shares shall vest and become exercisable in full on May 25, 2023. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| May 27, 2022 Filed Jun 2, 2022 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Unit · Derivative | 3,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006008 · form4-06012022_090621.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,534 Underlying: Common Stock · 3,534 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU shall vest in full on May 25, 2023. The RSU will become fully vested in the event that the Issuer is subject to a change in control. F2 · derivative.expiration_date: The RSU shall vest in full on May 25, 2023. The RSU will become fully vested in the event that the Issuer is subject to a change in control. Read SEC document |
| May 25, 2022 Filed May 28, 2022 01:45 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionRestricted Stock Unit · Derivative | 1,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005858 · form4-05272022_090501.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU vested in full on May 25, 2022. F2 · derivative.expiration_date: The RSU vested in full on May 25, 2022. Read SEC document |
| May 25, 2022 Filed May 28, 2022 01:45 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 1,307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-005858 · form4-05272022_090501.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001209191-22-028685 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-05-10 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.